In the CheckMate 026 study, nivolumab treatment did not improve OS (median OS 14.4 months for nivolumab vs. 13.2 months for chemotherapy) or PFS (median PFS 4.2 months for nivolumab vs. 5.9 months for chemotherapy) in previously untreated patients with stage IV or recurrence of NSCLC with PD-L1 expression on at least 5% of tumor cells, or in the subgroup of patients with PD-L1 expression on ≥50% of tumor cells. Here, CD274 is linked to neoplasm.